Skip to main content
. 2022 Jan 4;12(5):1349–1359. doi: 10.1016/j.jceh.2021.12.016

Figure 4.

Figure 4

Summary of preliminary evidence for clinical benefits with healthy donor fecal microbiota transplantation (FMT) in patients with severe alcohol-associated liver disease. For detailed discussion, please refer to text section on FMT under “Clinical studies on GM modulation and outcomes in ALD.” AH—alcohol-associated hepatitis, ACLF—acute on chronic liver failure, HE—hepatic encephalopathy, PHT—portal hypertension, and SC—standard care.